IS7384A - Stöðug lyfjablanda sem felur í sér torsemíð afbrigði II - Google Patents

Stöðug lyfjablanda sem felur í sér torsemíð afbrigði II

Info

Publication number
IS7384A
IS7384A IS7384A IS7384A IS7384A IS 7384 A IS7384 A IS 7384A IS 7384 A IS7384 A IS 7384A IS 7384 A IS7384 A IS 7384A IS 7384 A IS7384 A IS 7384A
Authority
IS
Iceland
Prior art keywords
torsemide
variant
pharmaceutical composition
continuous pharmaceutical
continuous
Prior art date
Application number
IS7384A
Other languages
English (en)
Inventor
Leibovici Minutza
Tenengauzer Ruth
Kopel Mira
Aronhime Judith
Kordova Marko
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS7384A publication Critical patent/IS7384A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
IS7384A 2002-02-08 2004-08-05 Stöðug lyfjablanda sem felur í sér torsemíð afbrigði II IS7384A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/071,423 US20030022921A1 (en) 2001-02-21 2002-02-08 Stable pharmaceutical formulation comprising torsemide modification II
PCT/US2003/003701 WO2003066023A1 (en) 2002-02-08 2003-02-07 A stable pharmaceutical formulation comprising torsemide modification ii

Publications (1)

Publication Number Publication Date
IS7384A true IS7384A (is) 2004-08-05

Family

ID=27732277

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7384A IS7384A (is) 2002-02-08 2004-08-05 Stöðug lyfjablanda sem felur í sér torsemíð afbrigði II

Country Status (16)

Country Link
US (1) US20030022921A1 (is)
EP (1) EP1359900A4 (is)
JP (1) JP2005518422A (is)
KR (1) KR20040081183A (is)
CN (1) CN1646094A (is)
AU (1) AU2003210903A1 (is)
CA (1) CA2455881A1 (is)
DE (1) DE03702168T1 (is)
ES (1) ES2209686T1 (is)
HR (1) HRP20040757A2 (is)
IS (1) IS7384A (is)
MX (1) MXPA04007695A (is)
NO (1) NO20043749L (is)
PL (1) PL372221A1 (is)
WO (1) WO2003066023A1 (is)
ZA (1) ZA200406026B (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2039349A1 (en) * 2004-10-19 2009-03-25 KRKA, tovarna zdravil, d.d., Novo mesto Solid pharmaceutical composition comprising donepezil hydrochloride
CN114641278A (zh) * 2019-09-11 2022-06-17 百时美施贵宝公司 吲哚胺2,3-双加氧酶抑制剂的药物配制品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE69624559T2 (de) * 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
KR20020025217A (ko) * 1999-08-11 2002-04-03 추후보정 토르세미드 동질이상
ES2193007T3 (es) * 2000-02-17 2004-11-01 Teva Pharmaceutical Industries Ltd. Formulacion farmaceutica estable que comprende la modificacion ii de la torsemida.
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide

Also Published As

Publication number Publication date
ES2209686T1 (es) 2004-07-01
WO2003066023A1 (en) 2003-08-14
US20030022921A1 (en) 2003-01-30
WO2003066023A9 (en) 2003-11-20
CA2455881A1 (en) 2003-08-14
DE03702168T1 (de) 2004-07-08
PL372221A1 (en) 2005-07-11
MXPA04007695A (es) 2004-12-07
CN1646094A (zh) 2005-07-27
EP1359900A1 (en) 2003-11-12
KR20040081183A (ko) 2004-09-20
AU2003210903A1 (en) 2003-09-02
EP1359900A4 (en) 2004-05-19
ZA200406026B (en) 2006-07-26
NO20043749L (no) 2004-09-07
JP2005518422A (ja) 2005-06-23
HRP20040757A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
GB2389530B (en) Pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
ATE380544T1 (de) Umhüllte feste darreichungsform
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
IL164547A0 (en) Pharmaceutical composition
DK1587478T3 (da) Farmaceutisk sammensætning
AU2003250372A8 (en) Pharmaceutical composition
DK3494995T3 (da) Superfin formoterolformulering
GB2391473B (en) Pharmaceutical compositions
IS8351A (is) Lyfjaafurðir sem fela í sér bisfosfónöt
DE60310914D1 (de) Pulverzusammensetzung
EP1648364A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION
AU2003260803A8 (en) Sustained release pharmaceutical composition
NO20052952D0 (no) Farmasoytisk sammensetning som innbefatter mikropartikler
IS7458A (is) Stöðug lyfjablanda sem inniheldur þátt VIII
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
IS7488A (is) Dreyfasamsetning í föstu formi
GB0213481D0 (en) Pharmaceutical compositions
GB0300885D0 (en) Pharmaceutical composition
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
NO20044164L (no) Farmasoytiske sammensetninger
GB0217703D0 (en) Pharmaceutical composition
DOP2002000508A (es) Composición farmaceutica
ITMI20020926A1 (it) Composizioni farmaceutiche riepitelizzanti
GB0214491D0 (en) Pharmaceutical composition